A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity

INTRODUCTION: Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinelli, Lucio, Balestrino, Maurizio, Mori, Laura, Puce, Luca, Rosa, Gian Marco, Giorello, Laura, Currà, Antonio, Fattapposta, Francesco, Serrati, Carlo, Gandolfo, Carlo, Abbruzzese, Giovanni, Trompetto, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595207/
https://www.ncbi.nlm.nih.gov/pubmed/28882919
http://dx.doi.org/10.1136/bmjopen-2017-016843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595207/
https://www.ncbi.nlm.nih.gov/pubmed/28882919
http://dx.doi.org/10.1136/bmjopen-2017-016843

Ejemplares similares